Evidence map›Paper›PMID 36895786›Full record

ArticleStem cells international2023

Construction of a TTN Mutation-Based Prognostic Model for Evaluating Immune Microenvironment, Cancer Stemness, and Outcomes of Colorectal Cancer Patients.

Lei Zhao, Weiwei Fan, Kunpeng Luo, Siqi Xie, Rui Wang, Jingming Guan, Zhendong Chen, Shizhu Jin

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cross-talk of mFrontiers in immunology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lei ZhaoDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0002-7883-2849
Weiwei FanDepartment of Infectious Medicine, Heilongjiang Provincial Hospital, Harbin, China.ORCID https://orcid.org/0000-0003-4158-5052
Kunpeng LuoDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0002-3923-6630
Siqi XieDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0002-3317-0810
Rui WangDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0002-0685-044X
Jingming GuanDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0002-6738-7081
Zhendong ChenDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0001-7355-7086
Shizhu JinDepartment of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0003-3613-0926
Harbin Medical University · CNHeilongjiang Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is one of the commonest cancers worldwide. As conventional biomarkers cannot clearly define the heterogeneity of CRC, it is essential to establish novel prognostic models. Methods: For the training set, data pertaining to mutations, gene expression profiles, and clinical parameters were obtained from the Cancer Genome Atlas. Consensus clustering analysis was used to identify the CRC immune subtypes. CIBERSORT was used to analyze the immune heterogeneity across different CRC subgroups. Least absolute shrinkage and selection operator regression was used to identify the genes for constructing the immune feature-based prognostic model and to determine their coefficients. Result: A gene prognostic model was then constructed to predict patient outcomes; the model was then externally validated using data from the Gene Expression Omnibus. As a high-frequency somatic mutation, the titin (TTN) mutation has been identified as a risk factor for CRC. Our results demonstrated that TTN mutations have the potential to modulate the tumor microenvironment, converting it into the immunosuppressive type. In this study, we identified the immune subtypes of CRC. Based on the identified subtypes, 25 genes were selected for prognostic model construction; a prediction model was also constructed, and its prediction accuracy was tested using the validation dataset. The potential of the model in predicting immunotherapy responsiveness was then explored. Conclusion: TTN-mutant and TTN-wild-type CRC demonstrated different microenvironment features and prognosis. Our model provides a robust immune-related gene prognostic tool and a series of gene signatures for evaluating the immune features, cancer stemness, and prognosis of CRC.

Identifiers

PMID36895786
PMCPMC9990748
OpenAlexW4321434496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.